Current aspects in treatment of breast cancer based of nanodrug delivery systems and future prospects
Source abstract
Abstract
Breast cancer is one of the most common diseases worldwide. The risk of getting this disease in female is 30% and the mortality rate is 14%. The breast cancer treatment is based on surgery, chemotherapy and radiotherapy. However, an effective treatment method has not been developed. The main cause of failure in the treatment is cancer stem cells metastasis and chemo-resistance. The use of nanocarrier systems against breast cancer stem cells has great importance. Not only advantages of polymeric drug delivery systems are increasing the stability and reduce the side effects of drugs, but also they have disadvantages such as biocompatibility and long-term potential safety. However, in recent years, studies on exosomes provide several advantages. Exosomes usage as nanocarrier do not cause immunological reactions also the drug effectively transport into the cytosol of targeted cell and have more stability characteristics. Although there are studies about various nanocarrier systems in literature against breast cancer but in general, we have not found any review that brings them together and develops a systematic approach to solving the problem. This review mentions prospective new strategies based on various nanocarrier systems and emphasize the importance of exosome based on drug delivery systems in the treatment of breast cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Extracellular vesicles in disease · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Faculty of Chemical and Metallurgical Engineering, Department of Bioengineering, Yildiz Technical University
Funding
Yildiz Technical University
References (50)
Show source-provided references
1. 10.1155/2013/96082110.1155/2013/960821 ↗
2. 10.1080/21691401.2017.136633710.1080/21691401.2017.1366337 ↗
3. Allahverdiyev AM, Bagirova M, Oztel ON, et al. Aldehyde dehydrogenase: cancer and stem cells. Rijeka: InTech; 2012.
4. 10.2147/IJN.S14032510.2147/IJN.S140325 ↗
5. 10.3390/ijms1812257410.3390/ijms18122574 ↗
6. Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology. 2014;28:1101–1107.
7. 10.1016/j.bbacli.2017.01.00110.1016/j.bbacli.2017.01.001 ↗
8. 10.4048/jbc.2015.18.4.30310.4048/jbc.2015.18.4.303 ↗
9. 10.2217/nnm.12.8710.2217/nnm.12.87 ↗
10. 10.2147/IJN.S3383810.2147/IJN.S33838 ↗
11. 10.3389/fphar.2017.0000110.3389/fphar.2017.00001 ↗
12. 10.1186/1556-276X-7-14410.1186/1556-276X-7-144 ↗
13. 10.1016/j.addr.2008.03.01810.1016/j.addr.2008.03.018 ↗
14. 10.1088/0957-4484/27/6/06510310.1088/0957-4484/27/6/065103 ↗
15. 10.1016/j.nano.2018.04.01910.1016/j.nano.2018.04.019 ↗
16. 10.2147/NSA.S378810.2147/NSA.S3788 ↗
17. 10.1259/bjr/5944883310.1259/bjr/59448833 ↗
18. 10.1111/cpr.1229610.1111/cpr.12296 ↗
19. 10.1007/s10439-005-9002-710.1007/s10439-005-9002-7 ↗
20. 10.4143/crt.2016.09110.4143/crt.2016.091 ↗
21. 10.21037/qims.2017.02.0910.21037/qims.2017.02.09 ↗
22. 10.1111/ajco.1243710.1111/ajco.12437 ↗
23. 10.1016/j.coche.2014.12.00310.1016/j.coche.2014.12.003 ↗
24. 10.2147/IJN.S1692310.2147/IJN.S16923 ↗
25. 10.1007/s12013-014-0363-010.1007/s12013-014-0363-0 ↗
26. 10.4172/1948-5956.100002410.4172/1948-5956.1000024 ↗
27. 10.1097/01.cad.0000167902.53039.5a10.1097/01.cad.0000167902.53039.5a ↗
28. 10.1016/j.ejps.2018.04.04010.1016/j.ejps.2018.04.040 ↗
29. 10.1002/jbm.a.3636010.1002/jbm.a.36360 ↗
30. Derman S, Akdeste ZM, Ates SC, et al. The study of syntetic peptide loaded PLGA nanoparticles cytotoxicity in vitro. Fres Environ Bull. 2017;26:1646–1653.
31. 10.3389/fphar.2016.0031310.3389/fphar.2016.00313 ↗
32. 10.2217/nnm.10.1010.2217/nnm.10.10 ↗
33. 10.1016/j.jconrel.2017.08.02510.1016/j.jconrel.2017.08.025 ↗
34. 10.1016/j.eurpolymj.2018.04.02010.1016/j.eurpolymj.2018.04.020 ↗
35. 10.1073/pnas.152126511310.1073/pnas.1521265113 ↗
36. 10.1158/1078-0432.CCR-07-144110.1158/1078-0432.CCR-07-1441 ↗
37. 10.1016/j.biomaterials.2016.11.00110.1016/j.biomaterials.2016.11.001 ↗
38. 10.1016/j.jddst.2018.03.02710.1016/j.jddst.2018.03.027 ↗
39. 10.1021/nl072209h10.1021/nl072209h ↗
40. 10.1007/s10439-011-0415-110.1007/s10439-011-0415-1 ↗
41. 10.1016/j.bbcan.2014.04.00510.1016/j.bbcan.2014.04.005 ↗
42. 10.1002/pmic.20140023410.1002/pmic.201400234 ↗
43. 10.1039/c3tb21238f10.1039/c3tb21238f ↗
44. 10.1186/s12929-015-0195-210.1186/s12929-015-0195-2 ↗
45. 10.1016/j.apsb.2016.02.00110.1016/j.apsb.2016.02.001 ↗
46. 10.1016/j.biomaterials.2013.11.08310.1016/j.biomaterials.2013.11.083 ↗
47. 10.3390/ijms1806112210.3390/ijms18061122 ↗
48. 10.1038/s41598-018-19339-510.1038/s41598-018-19339-5 ↗
49. 10.1172/JCI8112910.1172/JCI81129 ↗
50. 10.1038/aps.2017.1210.1038/aps.2017.12 ↗